Oncotarget

Research Papers:

CD40-activated B cells induce anti-tumor immunity in vivo

Kerstin Wennhold _, Tanja M. Weber, Nela Klein-Gonzalez, Martin Thelen, Maria Garcia-Marquez, Geothy Chakupurakal, Anne Fiedler, Hans A. Schlösser, Rieke Fischer, Sebastian Theurich, Alexander Shimabukuro-Vornhagen and Michael von Bergwelt-Baildon

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:27740-27753. https://doi.org/10.18632/oncotarget.7720

Metrics: PDF 1714 views  |   HTML 2922 views  |   ?  


Abstract

Kerstin Wennhold1,*, Tanja M. Weber1,*, Nela Klein-Gonzalez2, Martin Thelen1, Maria Garcia-Marquez1, Geothy Chakupurakal1, Anne Fiedler1, Hans A. Schlösser1,3, Rieke Fischer4, Sebastian Theurich1,5, Alexander Shimabukuro-Vornhagen1,*, Michael von Bergwelt-Baildon1,*

1Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

2Department of Hematology, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain

3Department of General, Visceral and Cancer Surgery, University Hospital of Cologne, Cologne, Germany

4Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

5Laboratory for Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research Cologne, Cologne, Germany

*These authors have contributed equally to this work

Correspondence to:

Kerstin Wennhold, e-mail: Kerstin.wennhold@uk-koeln.de

Keywords: cellular adjuvant, CD40-activated B cells, cancer immunotherapy, antigen presentation, B cell

Received: December 15, 2015     Accepted: January 26, 2016     Published: February 25, 2016

ABSTRACT

The introduction of checkpoint inhibitors represents a major advance in cancer immunotherapy. Some studies on checkpoint inhibition demonstrate that combinatorial immunotherapies with secondary drivers of anti-tumor immunity provide beneficial effects for patients that do not show a strong endogenous immune response. CD40-activated B cells (CD40B cells) are potent antigen presenting cells by activating and expanding naïve and memory CD4+ and CD8+ and homing to the secondary lymphoid organs. In contrast to dendritic cells, the generation of highly pure CD40B cells is simple and time efficient and they can be expanded almost limitlessly from small blood samples of cancer patients. Here, we show that the vaccination with antigen-loaded CD40B cells induces a specific T-cell response in vivo comparable to that of dendritic cells. Moreover, we identify vaccination parameters, including injection route, cell dose and vaccination repetitions to optimize immunization and demonstrate that application of CD40B cells is safe in terms of toxicity in the recipient. We furthermore show that preventive immunization of tumor-bearing mice with tumor antigen-pulsed CD40B cells induces a protective anti-tumor immunity against B16.F10 melanomas and E.G7 lymphomas leading to reduced tumor growth. These results and our straightforward method of CD40B-cell generation underline the potential of CD40B cells for cancer immunotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7720